Dengue fever – a 30% breakthrough
Enlarge image


Dengue fever – a 30% breakthrough

13.09.2012 - Sanofi-Pasteur has suffered a setback with its dengue fever vaccine. It proved to be far less effective than originally hoped. But this is not the end of the story.

Results from a Phase IIb study conducted in Thailand revealed the vaccine had about 30% overall efficacy against dengue fever type 2. Originally, the French pharma hoped to achieve more than 70% efficacy. The compound did show strong results against types 1, 3 and 4 of the mosquito-borne disease. However patients with a type 2 infection, the most prevalent strain in Thailand at the time of the study, did not show a satisfactory response. The vaccine candidate is meant to protect against all four types viruses that cause dengue. The result leaves uncertainty on the future of a product that Sanofi estimates it could generate more than €1bn in annual sales. Sanofi has invested €350m in a site to manufacture the vaccine. Still, the vaccine shows promise and Phase III studies involving more than 31,000 children and adults are under way in 10 countries across Asia and Latin America.

Dengue fever, a mosquito-borne disease, also known as "breakbone fever", is a threat to nearly 3 billion people in tropical regions. "This result knocked me off my chair," Scott Halstead, a senior scientific adviser for the non-profit Dengue Vaccine Initiative, who was not involved in the study, told Reuters. Sanofi had already published topline data in July saying that the study had shown efficacy against three of the four strains. However, the company did not present any details. The full findings were published online in the The Lancet. If the Thai trial results had been as strong as expected, Sanofi could have filed for early approval in some countries. Instead, Sanofi now has to wait for the phase III results. A commercial launch can now happen in 2015 or later.


Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


15.09.2015 German Merck’s biopharma business Merck Serono has laid the cornerstone for its newest R&D facility. The laboratory represents an investment of €65m.


14.09.2015 The long summer resulted in a lull in the life science sector’s stock market activities, but now the speed is picking up again. Acacia, Faron and Shield have all taken the plunge on the London Stock Exchange, while others are filing overseas.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.06 CHF20.00%
  • PROTHENA PLC (IE)49.54 USD9.14%
  • BIOFRONTERA (D)2.27 EUR7.08%


  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • CHRONTECH PHARMA (S)0.38 SEK3700.0%
  • THROMBOGENICS (B)3.84 EUR34.7%
  • OREXO (S)60.75 SEK22.2%


  • TRANSGENE (F)2.64 EUR-45.3%
  • GALAPAGOS (B)36.57 EUR-28.9%


  • KARO BIO (S)45.50 SEK4740.4%
  • CHRONTECH PHARMA (S)0.38 SEK375.0%
  • VERONA PHARMA (UK)4.55 GBP237.0%


  • NEOVACS (F)0.69 EUR-80.5%
  • BIOTEST (D)17.90 EUR-77.1%

No liability assumed, Date: 03.10.2015